吃瓜不打烊

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Healthcare Helpline
    • 吃瓜不打烊 Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • Common Ground
    • Diagnosis: Debt
    • The Body Shops
    • Priced Out
    • Guns, Race, and Profit
    • Broken Rehab
    • Dead Zone
    • Denied
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Healthcare Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health
    All Topics

  • Medicare Advantage Billing Probe
  • School Vaccine Mandates
  • Weight Loss Drugs Coverage
  • Opioid Settlement Money
  • Abortion Pill Access

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Feb 24 2021

Full Issue

Perspectives: PBMs Are Key To Solving High Drug Costs; Basic Biopharma Research Helps Everyone

Read recent commentaries about drug-cost issues.

As the Biden administration and the new Congress examine policies to reduce prescription drug costs, one place to start is officially revoking the so-called rebate rule, which was hastily 鈥 and likely illegally 鈥 finalized in the remaining days of the Trump administration.聽The rebate rule clumsily attempts to eliminate the primary tool used by pharmacy benefit managers, or PBMs, to negotiate increased access to affordable prescription drugs with drug manufacturers. The rule would not reduce drug costs: Centers for Medicare and Medicaid Services actuaries and the Congressional Budget Office have said it would significantly increase Medicare Part D premiums and add nearly $200 billion in Part D program costs for taxpayers. (JC Scott, 2/18)

Are you among the 98.5 percent of Americans taking prescription medications annually who fill them in the U.S. 鈥 too frightened by safety concerns or of doing something illegal to fill them abroad? The same brand name prescription drugs cost on average 3.5 times as much in the U.S. as in comparable high-income countries. Or are you among the 30 percent of Americans who cannot even afford to fill your prescriptions?聽To lower drug prices, more than three-quarters of Democratic, Republican and Independent voters favor policies that promote imports and that harness Medicare鈥檚 market power. We propose new legislation that distills the best ideas in Democratic-sponsored bills with the best ideas in two of President Trump鈥檚 recent executive orders. This legislation can deliver a one-two punch to high prescription drug prices.聽 (Stephen Salant and Gabriel Levitt, 2/17)

I鈥檓 always very appreciative that MarketWatch readers take the time to write. I focus on retirement issues, and one of the more common emails I get concerns soaring drug prices. The average medication went up 4.2% in January, according to an analysis by GoodRx, a medical and health care services provider 鈥 a rate three times faster than the 1.3% increase in Social Security. Some retirees are getting hit even worse. Here鈥檚 an excerpt from one email, from 鈥淩AB,鈥 who worries that she and her husband could lose their home because they鈥檝e fallen behind on their taxes. One reason for this: their medical bills are through the roof. (Paul Brandus, 2/20)

Americans are grateful for the COVID-19 vaccines 鈥 quickly produced, safe and effective, and currently free to receive 鈥 and await their turn to receive their shots. Yet, far too many of us cannot afford the drugs vital to our health.聽Drug corporations continue to make hefty profits from setting drug prices that far exceed prices for the same drugs in other countries and from raising prices on older drugs just because they can. (Lisa Bero, Mark Levine, Dean Baker and Aaron Kesselheim, 2/21)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Thursday, August 6
  • Wednesday, August 5
  • Tuesday, August 4
  • Monday, August 3
  • Friday, July 31
  • Thursday, July 30
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • 吃瓜不打烊
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

漏 2026 KFF